QC
FDMT icon

Quadrature Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Quadrature Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$303K Buy
+32,524
New +$283K ﹤0.01% 978
2025
Q3 		– Sell
-11,257
Closed -$41.8K – 1175
2025
Q2 		$41.8K Buy
+11,257
New +$39.6K ﹤0.01% 965

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Quadrature Capital's FDMT Position: Q1 2026 in Review

Quadrature Capital opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 32,524 shares worth $303K. The stake represents ﹤0.01% of the portfolio and ranks #978 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in FDMT as recently as Q2 2025.

Quadrature Capital first reported a position in FDMT in Q2 2025 and has held it in 2 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Quadrature Capital held 32,524 shares of 4D Molecular Therapeutics worth $303K as of Q1 2026.
  • 4D Molecular Therapeutics was a new Quadrature Capital position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #978 holding.
  • Quadrature Capital first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.